Blog - Page 31 of 5409 - QualityStocks

FridayJun 27, 2025 10:30 am

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Breaks Ground on REE Processing Facility, Pioneers Domestic Supply Chain

The company announced the groundbreaking of its Louisiana Strategic Metals Complex (“SMC”) in Alexandria. The Louisiana SMC is designed to utilize Ucore's proprietary RapidSX(TM) technology. Ucore also announced the execution of $18.4 million in funding from the U.S. Department of Defense (“DoD”). Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America, has marked a significant milestone in the development of a domestic REE supply chain. The company announced the groundbreaking of its Louisiana Strategic Metals Complex (“SMC”) in Alexandria (https://ibn.fm/zPMiw). This facility represents the company's first…

FridayJun 27, 2025 10:20 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released a shareholder letter from CEO Eric Poma, PhD, outlining a transformative year for the company. Since Poma’s appointment in April 2025 and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has streamlined operations and advanced its RedTail platform—a systemically delivered virotherapy designed to target metastatic cancers and deliver genetic payloads. Preclinical data presented at AACR and ASCO showcased RedTail’s tumor selectivity and immune modulation potential, driving partnership discussions and IND-enabling studies for lead candidate CLD-401, with a filing expected by end…

FridayJun 27, 2025 9:45 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health priorities. NRX-100, a preservative-free ketamine, is also under an Abbreviated New Drug Application (“ANDA”) with a priority review request. NRx has submitted full CMC data and draft labeling for NRX-100, meeting key Commissioner's National Priority Voucher pre-qualification criteria. The company’s U.S.-based manufacturing aims to reduce foreign supply chain dependence and address diversion concerns. A patent on the preservative-free process and a citizen petition to withdraw preserved ketamine could bolster NRx’s market position. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal…

FridayJun 27, 2025 9:00 am

AI World Society Circle Presents:After Hours AI World Society Circle SFO Chapter

AI World Society Circle (“AIWS”) is proud to announce the San Francisco Chapter of its flagship After Hours AI World Society Circle event. This exclusive evening experience will offer a unique opportunity for attendees to connect with fellow AI enthusiasts, industry leaders, and innovators in a relaxed and positive atmosphere. It will offer unrivaled networking opportunities, engaging discussions, expert insights, as well as AI start-up pitches, allowing attendees to stay ahead of the curve on all matters AI. AIWS is a global initiative dedicated to promoting ethical AI governance and responsible AI development. It is an institution that believes in…

ThursdayJun 26, 2025 3:45 pm

QualityStocksNewsBreaks – Adageis Brings Key Advantages in Pivot to Value-Based Healthcare

Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward value-based care. “One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards,” reads a recent article. “Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims…

ThursdayJun 26, 2025 3:05 pm

QualityStocksNewsBreaks – Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Advancing Strategic Path in Resurging Market

Platinum Group Metals (NYSE American: PLG) (TSX: PTM) is well positioned as platinum and palladium prices have gained considerable momentum in recent weeks, driven largely by a resurgence in demand from China’s jewelry sector and increasing concern over global supply constraints. “With a strong asset base and an advanced development project in South Africa, the company is pursuing a strategic path toward becoming an important supplier in a resurging PGM market,” reads an article discussing the company. “Platinum Group Metals is making meaningful strides through its flagship Waterberg Project, a large-scale palladium-dominant deposit located on the Northern Limb of South Africa’s…

ThursdayJun 26, 2025 11:32 am

QualityStocksNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Sees 245% Surge in Juve Stabia Valuation Following Promotion Playoff Run

Brera Holdings (NASDAQ: BREA), an Ireland-based company executing a multi-club ownership strategy in global football, announced that its portfolio club S.S. Juve Stabia recorded the highest market value increase in Italy’s Serie B for the 2024–25 season. According to Virgilio Sport, the club’s valuation rose 245% to US$32 million, driven by a strong on-field performance and promotion playoff run. Brera finalized its 52% controlling stake in Juve Stabia on June 20, 2025, following FIGC approval. Executive Chairman Daniel McClory credited the growth to Brera’s operational and player development strategy. To view the full press release, visit https://ibn.fm/ZJHvS About Brera Holdings…

ThursdayJun 26, 2025 10:30 am

ONAR Holding Corp. (ONAR): Why Smart Agencies Are Choosing Algorithms Over Assumptions

ONAR's technology-first approach combines its proprietary AI platform with strategic agency acquisitions to deliver measurable marketing results for middle-market companies Recent board appointment of advertising innovator Jon Bond reinforces ONAR's positioning at the intersection of creativity and technology in the evolving martech landscape The company's integrated model leverages AI automation across performance media, SEO, and healthcare marketing through its network of agencies The marketing technology sector finds itself at a crossroads that extends far beyond the typical innovation cycle. As adtech companies scramble to incorporate artificial intelligence into their offerings, launching everything from automated creative platforms to machine learning optimization…

ThursdayJun 26, 2025 10:15 am

QualityStocksNewsBreaks – Channelchek by Noble Highlights Steelcase (NYSE: SCS) Beats Q1 FY26 Expectations with Strong Margins and EPS Upside

Channelchek, a Noble Financial Group, Inc. product and service, reports that Steelcase (NYSE: SCS) delivered first-quarter fiscal 2026 results ahead of expectations, with revenue rising 7% year over year to $779 million—above both the $760 million forecast and $762 million consensus. Gross margin improved to 33.9%, surpassing guidance, while adjusted EPS reached $0.20, topping Noble’s $0.14 estimate and the $0.13 Street consensus. Strength in the Americas, especially among corporate, government, and healthcare customers, drove the gains. Orders dipped slightly overall, with 1% growth internationally offset by a 1% decline in the Americas. Looking ahead, Steelcase expects flat to 4% revenue…

ThursdayJun 26, 2025 9:45 am

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial

Lantern Pharma uses a proprietary AI platform, RADR®, to guide its oncology drug development, enabling rapid drug candidate identification and targeted trial design based on genomic and biomarker data. A Phase 2 trial patient achieved a complete response in their primary cancer lesions after multiple prior therapies failed and has remained responsive to LP-300 for two years signaling durable clinical benefit in this challenging population. The target population, never-smokers with non-small cell lung cancer, represents a growing global unmet need estimated at over $4 billion annually. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning…

Site Search

Company Search